Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 89-111

  Ulusoy, Ayse ^a   Decressac, Mickael ^a   Kirik, Deniz ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adeno associated virus; Animal models; Dopamine; Lentivirus; Motor impairment; Nigrostriatal system; Synuclein; Viral vectors

Indexed keywords

ALPHA SYNUCLEIN; LENTIVIRUS VECTOR; VIRUS VECTOR;

ADENOVIRUS; BOOK; CELL DEATH; COGNITION; DISEASE MODEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HUMAN; MESENCEPHALON; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

EID: 77957224859     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84005-1     Document Type: Chapter

References (114)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Adamczyk A., Kazmierczak A., Strosznajder J.B. Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochemistry International 2006, 49:407-412.
3. Alerte T.N., Akinfolarin A.A., Friedrich E.E., Mader S.A., Hong C.S., Perez R.G. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neuroscience Letters 2008, 435:24-29.
4. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. Journal of Biological Chemistry 2006, 281:29739-29752.
5. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Human Molecular Genetics 2009, 18:872-887.
6. Bjorklund T., Hall H., Breysse N., Soneson C., Carlsson T., Mandel R.J., et al. Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. Journal of Neurochemistry 2009, 111:355-367.
7. Braak H., Braak E. Pathoanatomy of Parkinson's disease. Journal of Neurology 2000, 247(Suppl. 2):II3-II10.
8. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003, 24:197-211.
9. Brockstedt D.G., Podsakoff G.M., Fong L., Kurtzman G., Mueller-Ruchholtz W., Engleman E.G. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clinical Immunology 1999, 92:67-75.
10. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. Journal of Neuroscience 2002, 22:8797-8807.
11. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB Journal 2005, 19:1377-1379.
12. Ceregene presents additional clinical data from phase 2 trial of CERE-120 for Parkinson's disease Ceregene. http://wwwceregenecom/press_052709asp.
13. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neuroscience 2005, 8:657-663.
14. Chirmule N., Xiao W., Truneh A., Schnell M.A., Hughes J.V., Zoltick P., et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. Journal of Virology 2000, 74(2420-2425).
15. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. Journal of Neuroscience 2009, 29:3365-3373.
16. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., et al. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Annals of the New York Academy of Sciences 2000, 920:42-45.
17. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
18. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Letters 1998, 436:309-312.
19. Daher J.P., Ying M., Banerjee R., McDonald R.S., Hahn M.D., Yang L., et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Molecular Neurodegeneration 2009, 4:34.
20. Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3428-3432.
21. Dodiya H.B., Bjorklund T., Stansell J., Mandel R.J., Kirik D., Kordower J.H. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Molecular Therapy 2010, 18:579-587.
22. Duke D.C., Moran L.B., Pearce R.K., Graeber M.B. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007, 8:83-94.
23. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. Journal of Neuroscience 2005, 25:769-777.
24. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
25. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of Neurology 1996, 40:873-884.
26. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology 2002, 4:160-164.
27. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13450-13455.
28. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. Journal of Neuroscience 2008, 28:7687-7698.
29. Georgievska B., Kirik D., Rosenblad C., Lundberg C., Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 2002, 13:75-82.
30. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006, 21:404-412.
31. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
32. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 2003, 9:589-595.
33. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:763-768.
34. Grimm D., Kern A., Rittner K., Kleinschmidt J.A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Human Gene Therapy 1998, 9:2745-2760.
35. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. Journal of Biological Chemistry 2002, 277:49071-49076.
36. Hashimoto M., Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathology 1999, 9:707-720.
37. Herrera F.E., Chesi A., Paleologou K.E., Schmid A., Munoz A., Vendruscolo M., et al. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 2008, 3:e3394.
38. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neuroscience Letters 1994, 182(107-111).
39. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. Journal of Neuroscience 1998, 18:4929-4937.
40. Ichimura T., Isobe T., Okuyama T., Takahashi N., Araki K., Kuwano R., et al. Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:7084-7088.
41. Ichimura T., Isobe T., Okuyama T., Yamauchi T., Fujisawa H. Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+,calmodulin-dependent protein kinase II. FEBS Letters 1987, 219:79-82.
42. Kahle P.J., Neumann M., Ozmen L., Haass C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Annals of the New York Academy of Sciences 2000, 920:33-41.
43. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA: Time dependence and requirement for protein synthesis. Journal of Neuroscience 1997, 17:7111-7118.
44. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: A new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2884-2889.
45. Kirik D., Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences 2003, 26:386-392.
46. Kirik D., Georgievska B., Rosenblad C., Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. The European Journal of Neuroscience 2001, 13:1589-1599.
47. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Journal of Neuroscience 2002, 22:2780-2791.
48. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Human Gene Therapy 2002, 13:605-612.
49. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
50. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology 2006, 60:706-715.
51. Larsen K.E., Schmitz Y., Troyer M.D., Mosharov E., Dietrich P., Quazi A.Z., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. Journal of Neuroscience 2006, 26:11915-11922.
52. Lauwers E., Beque D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiology of Aging 2007, 28:248-257.
53. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathology 2003, 13:364-372.
54. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB Journal 2001, 15:916-926.
55. Li J., Zhu M., Rajamani S., Uversky V.N., Fink A.L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chemistry and Biology 2004, 11:1513-1521.
56. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. Journal of Biological Chemistry 2005, 280:22670-22678.
57. Lo Bianco C., Deglon N., Pralong W., Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiology of Disease 2004, 17:283-289.
58. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:10813-10818.
59. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:17510-17515.
60. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. Journal of Biological Chemistry 2002, 277:38884-38894.
61. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nature Reviews Neuroscience 2002, 3:932-942.
62. Maingay M., Romero-Ramos M., Carta M., Kirik D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease 2006, 23:522-532.
63. Manfredsson F.P., Burger C., Sullivan L.F., Muzyczka N., Lewin A.S., Mandel R.J. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Experimental Neurology 2007, 207:289-301.
64. Manning W.C., Paliard X., Zhou S., Pat Bland M., Lee A.Y., Hong K., et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. Journal of Virology 1997, 71:7960-7962.
65. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Annals of Neurology 2006, 60:256-260.
66. Mazzulli J.R., Mishizen A.J., Giasson B.I., Lynch D.R., Thomas S.A., Nakashima A., et al. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. Journal of Neuroscience 2006, 26:10068-10078.
67. Mbefo M.K., Paleologou K.E., Boucharaba A., Oueslati A., Schell H., Fournier M., et al. Phosphorylation of synucleins by members of the Polo-like kinase family. Journal of Biological Chemistry 2010, 285:2807-2822.
68. McFarland N.R., Fan Z., Xu K., Schwarzschild M.A., Feany M.B., Hyman B.T., et al. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology 2009, 68:515-524.
69. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Movement Disorder 2008, 23:474-483.
70. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
71. Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
72. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. Journal of Clinical Investigation 2002, 110:1429-1439.
73. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. Journal of Biological Chemistry 2005, 280:21212-21219.
74. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
75. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. Journal of Neuroscience 2000, 20:6048-6054.
76. Payton J.E., Perrin R.J., Woods W.S., George J.M. Structural determinants of PLD2 inhibition by alpha-synuclein. Journal of Molecular Biology 2004, 337:1001-1009.
77. Peden C.S., Burger C., Muzyczka N., Mandel R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. Journal of Virology 2004, 78:6344-6359.
78. Peden C.S., Manfredsson F.P., Reimsnider S.K., Poirier A.E., Burger C., Muzyczka N., et al. Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Molecular Therapy 2009, 17:524-537.
79. Peng X., Tehranian R., Dietrich P., Stefanis L., Perez R.G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. Journal of Cell Science 2005, 118:3523-3530.
80. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. Journal of Neuroscience 2002, 22:3090-3099.
81. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
82. Reimsnider S., Manfredsson F.P., Muzyczka N., Mandel R.J. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Molecular Therapy 2007, 15:1504-1511.
83. Rohr U.P., Heyd F., Neukirchen J., Wulf M.A., Queitsch I., Kroener-Lux G., et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. Journal of Virological Methods 2005, 127:40-45.
84. Rosenblad C., Georgievska B., Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. The European Journal of Neuroscience 2003, 17:260-270.
85. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience 1999, 11:1554-1566.
86. Saha A.R., Hill J., Utton M.A., Asuni A.A., Ackerley S., Grierson A.J., et al. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. Journal of Cell Science 2004, 117:1017-1024.
87. Sanchez-Guajardo V., Febbraro F., Kirik D., Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010, 5:e8784.
88. Shabram P., Aguilar-Cordova E. Multiplicity of infection/multiplicity of confusion. Molecular Therapy 2000, 2:420-421.
89. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology 2003, 179:9-16.
90. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
91. St Martin J.L., Klucken J., Outeiro T.F., Nguyen P., Keller-McGandy C., Cantuti-Castelvetri I., et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry 2007, 100:1449-1457.
92. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M., et al. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neuroscience Letters 2003, 336:155-158.
93. Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. Journal of Neuropathology and Experimental Neurology 2008, 67:1149-1158.
94. Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): Implications for Lewy body disorders. Journal of Neuroscience 2006, 26:3942-3950.
95. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
96. Toska K., Kleppe R., Armstrong C.G., Morrice N.A., Cohen P., Haavik J. Regulation of tyrosine hydroxylase by stress-activated protein kinases. Journal of Neurochemistry 2002, 83:775-783.
97. Ulusoy A., Bjorklund T., Hermening S., Kirik D. In vivo gene delivery for development of mammalian models for Parkinson's disease. Experimental Neurology 2008, 209:89-100.
98. Ulusoy, A., Febraro, F., Jensen, P.H., Kirik, D., & Romero-Ramos, M. (2010). Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. European Journal of Neuroscience doi: 10.111/j.1460-9568.2010.07284.x.
99. Ulusoy A., Sahin G., Bjorklund T., Aebischer P., Kirik D. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Molecular Therapy 2009, 17:1574-1584.
100. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Molecular Therapy 2006, 14:716-723.
101. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
102. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40:7812-7819.
103. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiology of Aging 2008, 29:574-585.
104. Wersinger C., Prou D., Vernier P., Niznik H.B., Sidhu A. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Molecular and Cellular Neuroscience 2003, 24:91-105.
105. Wersinger C., Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neuroscience Letters 2003, 340:189-192.
106. Wersinger C., Sidhu A. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 2005, 44:13612-13624.
107. Xu L., Daly T., Gao C., Flotte T.R., Song S., Byrne B.J., et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Human Gene Therapy 2001, 12:563-573.
108. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine 2002, 8:600-606.
109. Yakobson B., Koch T., Winocour E. Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. Journal of Virology 1987, 61:972-981.
110. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease. Journal of Neurochemistry 2004, 91:451-461.
111. Yasuda T., Miyachi S., Kitagawa R., Wada K., Nihira T., Ren Y.R., et al. Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 2007, 144:743-753.
112. Yamada M., Mizuno Y., Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease. Human Gene Therapy 2005, 16:262-270.
113. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999, 6:973-985.
114. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J., et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28:158-167.